AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-3.67%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$639M
AUM Growth
+$639M
(-0.21%)
Cap. Flow
+$95.5M
Cap. Flow
% of AUM
14.95%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
109
New
20
Increased
27
Reduced
17
Closed
13
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$16.8M |
| 2 |
Travere Therapeutics
TVTX
|
$15.6M |
| 3 |
Protagonist Therapeutics
PTGX
|
$13.1M |
| 4 |
Nuvalent
NUVL
|
$12.4M |
| 5 |
Mineralys Therapeutics
MLYS
|
$11.9M |
Top Sells
| 1 |
Arvinas
ARVN
|
$12.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$10.3M |
| 3 |
Soleno Therapeutics
SLNO
|
$5.72M |
| 4 |
Arrowhead Research
ARWR
|
$5.64M |
| 5 |
Spyre Therapeutics
SYRE
|
$5.53M |
Sector Composition
| 1 | Healthcare | 90.82% |
| 2 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
101
Arrowhead Research
ARWR
$3.84B
| – | – |
-300,000
| Closed | -$5.64M |
|
|
102
Arvinas
ARVN
$580M
| – | – |
-630,000
| Closed | -$12.1M |
|
103
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-50,000
| Closed | -$1.6M |
|
104
Amgen
AMGN
$153B
| – | – |
0
| – | – |
|
105
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
0
| – | – |
|